Evidence map›Paper›PMID 29730745›Full record

ArticleEuropean journal of epidemiology2018

The heart of the matter: years-saved from cardiovascular and cancer deaths in an elite athlete cohort with over a century of follow-up.

Juliana Antero-Jacquemin, Maja Pohar-Perme, Grégoire Rey, Jean-François Toussaint, Aurélien Latouche

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Juliana Antero-JacqueminInstitut de Recherche bioMédicale et d'Epidémiologie du Sport (IRMES), Institut National du Sport, de l'Expertise et de la Performance (INSEP), 11 Avenue du Tremblay, 75012, Paris, France. juliana.antero@insep.fr.
Maja Pohar-PermeInstitute of Biostastistics and Medical Informatics, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Grégoire ReyInserm CépiDc, Epidemiology Centre on Medical Causes of Death, Le Kremlin-Bicêtre, France.
Jean-François ToussaintInstitut de Recherche bioMédicale et d'Epidémiologie du Sport (IRMES), Institut National du Sport, de l'Expertise et de la Performance (INSEP), 11 Avenue du Tremblay, 75012, Paris, France.
Aurélien LatoucheConservatoire National des Arts et Métiers (CNAM), Paris, France.
Assistance Publique – Hôpitaux de Paris · FRCentre d'Épidémiologie sur les Causes Médicales de Décès · FRConservatoire National des Arts et Métiers · FRInstitut National du Sport, de l'Expertise et de la Performance · FRUniversity of Ljubljana · SI

Funding

Ministry of sports, youth, popular education and community life of France Project n°12-R-10
6 · The paper itself

Abstract

To quantify the years of life saved from cardiovascular (CVD), cancer and overall deaths among elite athletes according to their main type of physiological effort performed in the Olympic Games. All French athletes participating in the Games from 1912 to 2012, with vital status validated and cause of death (if concerned) identified by the national registries were included (n = 2814, 455 died) and classified according to 6 groups of effort: POWER (continuous effort < 45 s); INTERMEDIATE (45 s ≤ continuous effort < 600 s); ENDURANCE (continuous effort ≥ 600 s); POLYVALENT (participating in different events entering different classifications), INTERMITTENT (intermittent effort, i.e. team sports); PRECISION (targeting events). The theoretical years-lost method was adapted to calculate gains in longevity (years-saved) according to specific-risks under the competing risks model and was implemented in R software. Considering overall-deaths, all groups significantly saved, on average, 6.5 years of life (95% CI 5.8-7.2) compared to the general population. This longevity advantage is mainly driven by a lower risk of cancer which, isolated, contributed to significantly save 2.3 years of life (95% CI 1.2-1.9) on average in each group. The risk of CVD-related mortality in the ENDURANCE and PRECISION groups is not significantly different from the general population. The other groups significantly saved, on average, 1.6 years of life (95% CI 1.2-1.9) from CVD death. The longevity benefits in elite athletes are associated with the type of effort performed during their career, mainly due to differences on the CVD-risk of death.

Indexed as

AthletesAgedCardiovascular DiseasesCohort StudiesFemaleFranceHumansMaleNeoplasmsRegistriesAthletesCancerCardiovascularMortalityYears-lostYears-saved

Identifiers

PMID29730745
OpenAlexW2800474049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.